Tyra Biosciences (TYRA) vs UroGen Pharma (URGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
UroGen Pharma (URGN) has outperformed Tyra Biosciences (TYRA) over the past year, gaining 6.9% versus a loss of 4.7%. Over five years, URGN leads with a +127.8% price change compared with -15.7% for TYRA. Tyra Biosciences is the larger company by market cap ($1.39 billion vs $1.36 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TYRA | URGN |
|---|---|---|
| Share price | $20.12 | $27.65 |
| Market cap | $1.39B | $1.36B |
| 1-day change | +1.98% | -12.86% |
| YTD return | -23.47% | +18.06% |
| 1-year return | -4.73% | +6.88% |
| 5-year return | -15.71% | +127.76% |
| Forward P/E | — | 11.08 |
| EPS (TTM) | $-2.63 | $-1.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $109.79M |
| Revenue growth (YoY) | — | +21.45% |
| Net income (latest FY) | $-119.95M | $-153.49M |
| Gross margin | — | 88.66% |
| Operating margin | — | -113.73% |
| Net margin | — | -139.81% |
| 52-week high | $40.65 | $50.81 |
| 52-week low | $18.25 | $16.50 |
| Distance from 52-week high | -50.50% | -45.58% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +135.83% | +119.57% |
| Average volume | 852.56K | 1.11M |
| Shares outstanding | 69.08M | 49.05M |
| Employees | 87 | 300 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- URGN has outperformed TYRA by 11.6 percentage points over the past year.
About Tyra Biosciences
TYRA stock →Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
About UroGen Pharma
URGN stock →UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 300 employees
TYRA vs URGN FAQ
Which is bigger, Tyra Biosciences or UroGen Pharma?
Tyra Biosciences (TYRA) is larger, with a market capitalization of $1.39B compared with $1.36B for UroGen Pharma (URGN).
Which stock has performed better over the past year, TYRA or URGN?
URGN returned +6.88% over the past 12 months, compared with -4.73% for TYRA (price return, excluding dividends). Past performance does not predict future results.
Are Tyra Biosciences and UroGen Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.